Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navicixizumab Basket Study
NCT05453825Phase 2Unknown
- Sponsor
- OncXerna Therapeutics
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of navicixizumab in colorectal cancer (CRC), gastric cancer (GC), triple-negative breast cancer (TNBC), ovarian cancer, sponsored by OncXerna Therapeutics. Status: unknown.
02
Drugs
navicixizumab
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)triple-negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on NCT05453825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453825.